EP0000931A1 - Enzymatische Spaltung von N-acyl-Thienamycinen - Google Patents
Enzymatische Spaltung von N-acyl-Thienamycinen Download PDFInfo
- Publication number
- EP0000931A1 EP0000931A1 EP78100699A EP78100699A EP0000931A1 EP 0000931 A1 EP0000931 A1 EP 0000931A1 EP 78100699 A EP78100699 A EP 78100699A EP 78100699 A EP78100699 A EP 78100699A EP 0000931 A1 EP0000931 A1 EP 0000931A1
- Authority
- EP
- European Patent Office
- Prior art keywords
- thienamycin
- acyl
- process according
- carbon atoms
- enzyme
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D477/00—Heterocyclic compounds containing 1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula:, e.g. carbapenicillins, thienamycins; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulphur-containing hetero ring
- C07D477/10—Heterocyclic compounds containing 1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula:, e.g. carbapenicillins, thienamycins; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulphur-containing hetero ring with hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 4, and with a carbon atom having three bonds to hetero atoms with at the most one bond to halogen, e.g. an ester or nitrile radical, directly attached in position 2
- C07D477/12—Heterocyclic compounds containing 1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula:, e.g. carbapenicillins, thienamycins; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulphur-containing hetero ring with hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 4, and with a carbon atom having three bonds to hetero atoms with at the most one bond to halogen, e.g. an ester or nitrile radical, directly attached in position 2 with hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, attached in position 6
- C07D477/16—Heterocyclic compounds containing 1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula:, e.g. carbapenicillins, thienamycins; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulphur-containing hetero ring with hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 4, and with a carbon atom having three bonds to hetero atoms with at the most one bond to halogen, e.g. an ester or nitrile radical, directly attached in position 2 with hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, attached in position 6 with hetero atoms or carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. an ester or nitrile radical, directly attached in position 3
- C07D477/20—Sulfur atoms
Definitions
- the enzyme, penicillin amidohydrolase of bacterial or fungal origin is used on an industrial scale to catalyze the hydrolytic removal of the side chain of penicillin to give the nucleus 6-amino penicillanic acid (6-APA).
- This nucleus is the starting material for the synthesis of broad spectrum penicillins (semisynthetic) which are prepared by acylation of the amino group.
- a new antibiotic is thienamycin, (U.S. Patent No. 3,950,357).
- the teachings of U.S. Patent No. 3,950,357 are incorporated herein by reference.
- N-acyl derivatives of thienamycin are unexpectedly cleaved by penicillin amidohydrolase.
- the present invention provides a new process for conversion of N-acyl-thienamycins to thienamycin.
- N-acyl- thienamycin having the following structure: wherein R 1 and R 2 are independently selected from the group consisting of hydrogen (R and R 2 are not both hydrogen) or an acyl group is contacted in an aqueous medium with enzymes which are capable of removing the N-acyl moiety in order to form thienamycin.
- Thienamycin has the structure: Thienamycin is a valuable antibiotic which is active against both gram-positive and gram-negative bacteria.
- the enzymes utilized to remove the N-acyl moiety are penicillin amidohydrolases.
- the preferred compounds of this invention are those wherein R 1 is hydrogen and R 2 is acyl.
- acyl is meant the aliphatic and aromatic carboxylic acids including derivatives and analogs thereof such as thio analogs wherein the carbonyl oxygen is replaced by sulphur, diacyl radicals wherein R 1 and R 2 are joined together; as well as the sulphur and phosphorous acyl analogs such as substituted sulfonyl-, sulfinyl-, and sulfenyl-radicals, and substituted P(III) and P(V) radicals such as the substituted phosphorous-, phosphoric-, phosphonous- and phosphonic radicals, respectively.
- Such acyl radicals of the present invention are further defined below.
- the N-acyl derivatives may be prepared by any of the techniques well known in the art if the thienamycin has been isolated from the fermentation broth or solution. If the thienamycin has not been isolated from the fermentation broth, then the method of preparing the N-acyl-thienamycin is by reacting the appropriate acyl compound while the thienamycin is still in the broth or solution. Alternatively, the acyl group can be incorporated biosynthetically following supplementation of the fermentation broth with the parent acid or a derivative thereof. These derivatives, by virtue of their increased solubility in organic solvents and additional physical properties, provide alternate and more efficient routes for recovery of the thienamycin nucleus. Once the derivatized thienamycin is recovered from the broth or solution, it can be treated by the methods described in this invention in order to regenerate the thienamycin.
- the acyl radical represented by either R 1 or R 2 can, inter alia, be substituted or unsubstituted aliphatic, aromatic or heterocyclic, araliphatic or heterocylylaliphatic carboxylic acid radical, a substituted or unsubstituted carbamyl radical or a carbothioic acid radical.
- One group of acyl radicals can be represented by the general formula: wherein X is 0 or S and R" represents a straight or branched chain alkyl or alkoxymethylene group containing from 5-10 carbon atoms, aryloxymethylene, typically comprising 6-10 carbon atoms.
- Such above-listed groups can be unsubstituted or can be substituted by radicals such as OH, SH, SR (R is i loweralkyl or aryl such as phenyl), alkyl or alkoxy groups having 1 to about 6 carbon atoms, halo, such as Cl, Br, F and I, cyano, carboxy, sulfamino, carbamoyl, sulfonyl, azido, amino, substituted amino such as alkylamino including quaternary ammonium wherein the alkyl group comprises 1-6 carbon atoms, haloalkyl such as trifluoromethyl, carboxyalkyl, carbamoylalkyl, N-substituted carbamoylalkyl, wherein the alkyl moiety of the foregoing four radicals comprises 1 to about 6 carbon atoms, amidino, guanidino, N-substituted guanidino, guanidino lower alkyl and
- acyl groups that might be mentioned are those wherein R" is benzyl, phenoxymethylene, p-hydroxybenzyl, n-amyl, n-heptyl, 3- or 4-nitrobenzyl, phenethyl, ⁇ , ⁇ -diphenylethyl, methyldiphenylmethyl, triphenylmethyl, 2-methoxyphenyl, 2,6-dimethoxyphenyl, 2,4,6-trimethoxyphenyl, D-4-N-benzoylamino-4-carboxy-n-butyl, p-aminobenzyl, o-aminobenzyl, m-aminobenzyl, p-dimethylaminobenzyl, 2-ethoxy-l-napthyl, 4-guanidinomethylphenyl, 4-guanidinomethylbenzyl, 4-guanidinobenzyl, 4-guanidinophenyl, 2,6-dimethoxy-4-guanidino
- the preferred compounds that can be utilized in this invention that fit the above acyl radical description are phenylacetyl, p-hydroxyphenylacetyl, phenylglycyl, 2-thienylacetyl, phenoxyacetyl, N-propoxyacetyl and iso-butoxyacetyl.
- penicillin amidohydrolases to convert penicillins into 6-aminopenicillanic acid (6-APA) is known in the art.
- penicillin amidohydrolases to remove the N-acyl side chains of N-acylated thienamycin is surprising.
- the process of this invention may be conducted by reacting the starting material of the general formula I with the enzyme extract from a cultured broth, the filtrate or fermentation product of the Escherichia coli culture or a powder of the enzyme in an aqueous solution.
- the enzyme may be immobilized by adsorption or chemical reaction to an insoluble supporting structure such as glass, cellulose or agarose, and used to hydrolyse the N-acylated thienamycin either by contacting it in suspension, or by the percolation of the acylated material through a bed of the immobilized enzyme preparation.
- an insoluble supporting structure such as glass, cellulose or agarose
- the enzyme is capable of removing N-acyl moietys which were present or produced in fermentation broths as well as those N-acyl groups introduced during isolation of the antibiotic or made by chemical synthesis techniques.
- N-acylated thienamycin takes place in the presence of an enzyme of the microorganism of the genus Escherichia coli which is able to remove the acyl moiety to provide the antibiotic thienamycin.
- the amidohydrolase enzyme For the production of the amidohydrolase enzyme by cultivation of the above-mentioned microorganism, there may be used various culture media commonly employed for the cultivation of a microorganism. More specifically, glucose, sucrose, glycerol, starch, oils used for cultivation and the like as a carbon source and peptone, buillion, corn steep liquor, yeast extract, meat extract, fish meal, defatted soybean, wheat embryo and the like as a nitrogen source may be employed. If required, other additives may be employed in combination with the above. It is an advantage but not a necessity to include phenylacetic acid or its salts or derivatives in fermentation media.
- Escherichia coli is usually shaken or agitated under aeration.
- Cultivation temperature may range from about 23-27°C.
- Cultivation period is usually 20-28 hours.
- amidohydrolase contained in the cultured broth or its extract may be utilized in the present process without any further purification.
- the amidohydrolase enzyme may be precipitated with appropriate solvents, salted out or dialyzed or otherwise purified. It may be used free in solution or immobilized on an appropriat surface.
- a method utilized in the present invention is that of utilizing the whole cell amidohydrolase preparation. By this method, after cultivation, the culture is centrifuged to obtain the whole cells for subsequent reaction with the derivatized thienamycin.
- reaction mixtures are incubated 18 hours at 23°C.
- the assay plates are prepared as follows: An overnight growth of the assay organism, Staphylococcus aureus ATCC 6538P, in nutrient broth plus 0.2% yeast extract is diluted with nutrient broth, plus 0.2% yeast extract is diluted with nutrient broth, plus 0.2% yeast extract to a suspension having 60% transmittance at a wavelength of 660 nm. This suspension is added to Difco nutrient agar supplemented with 2.0 g./l. Difco yeast extract at 47°C. to 48°C., to make a composition containing 33.2 ml. of the suspension per liter of agar. Forty ml. of this suspension is poured into 22.5 cm. x 22.5 cm. petri plates, and these plates are chilled and held at 4°C. until used (5 days maximum).
- the TLC plate is removed and the assay plate incubated overnight at 37°C.
- the additional bioactive spots present at R f 0.39 and R f 0.45 in the enzyme-treated reaction mixtures containing phenylacetyl thienamycin and N-(O-formyl)-l-mandeloyl thienamycin are due to thienamycin produced by amdohydrolase enzyme reaction.
- a control containing buffer and enzyme alone produces no bioactive spots.
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US825883 | 1977-08-19 | ||
US05/825,883 US4162193A (en) | 1977-08-19 | 1977-08-19 | Enzymatic cleavage of N-acyl-thienamycins |
Publications (2)
Publication Number | Publication Date |
---|---|
EP0000931A1 true EP0000931A1 (de) | 1979-03-07 |
EP0000931B1 EP0000931B1 (de) | 1982-04-14 |
Family
ID=25245138
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP78100699A Expired EP0000931B1 (de) | 1977-08-19 | 1978-08-18 | Enzymatische Spaltung von N-acyl-Thienamycinen |
Country Status (9)
Country | Link |
---|---|
US (1) | US4162193A (de) |
EP (1) | EP0000931B1 (de) |
JP (1) | JPS5446890A (de) |
DE (1) | DE2861737D1 (de) |
DK (1) | DK365478A (de) |
ES (1) | ES472701A1 (de) |
IE (1) | IE47315B1 (de) |
IT (1) | IT1106626B (de) |
PT (1) | PT68428A (de) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH02135843U (de) * | 1988-11-08 | 1990-11-13 |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3260653A (en) * | 1959-04-18 | 1966-07-12 | Bayer Ag | Process for the production of 6-aminopenicillanic acid |
DE2652678A1 (de) * | 1975-11-24 | 1977-06-02 | Merck & Co Inc | Antibiotica und verfahren zur herstellung derselben |
NL7800958A (nl) * | 1977-02-11 | 1978-08-15 | Merck & Co Inc | Antibioticum desacetyl-dihydro 890 a9, werkwijze ter bereiding daarvan en farmaceutisch preparaat dat dit antibioticum bevat. |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CH475284A (de) * | 1963-11-19 | 1969-07-15 | Ciba Geigy | Verfahren zur Herstellung von Desacetyl-7-amino-cephalosporansäure |
JPS5417030B2 (de) * | 1972-12-06 | 1979-06-27 | ||
GB1474519A (de) * | 1973-05-14 | 1977-05-25 | ||
JPS5713280B2 (de) * | 1974-03-11 | 1982-03-16 | ||
US3950357A (en) * | 1974-11-25 | 1976-04-13 | Merck & Co., Inc. | Antibiotics |
-
1977
- 1977-08-19 US US05/825,883 patent/US4162193A/en not_active Expired - Lifetime
-
1978
- 1978-08-16 IT IT50747/78A patent/IT1106626B/it active
- 1978-08-16 PT PT68428A patent/PT68428A/pt unknown
- 1978-08-18 DK DK365478A patent/DK365478A/da not_active Application Discontinuation
- 1978-08-18 DE DE7878100699T patent/DE2861737D1/de not_active Expired
- 1978-08-18 ES ES472701A patent/ES472701A1/es not_active Expired
- 1978-08-18 IE IE1674/78A patent/IE47315B1/en unknown
- 1978-08-18 EP EP78100699A patent/EP0000931B1/de not_active Expired
- 1978-08-19 JP JP10046478A patent/JPS5446890A/ja active Granted
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3260653A (en) * | 1959-04-18 | 1966-07-12 | Bayer Ag | Process for the production of 6-aminopenicillanic acid |
DE2652678A1 (de) * | 1975-11-24 | 1977-06-02 | Merck & Co Inc | Antibiotica und verfahren zur herstellung derselben |
NL7800958A (nl) * | 1977-02-11 | 1978-08-15 | Merck & Co Inc | Antibioticum desacetyl-dihydro 890 a9, werkwijze ter bereiding daarvan en farmaceutisch preparaat dat dit antibioticum bevat. |
Also Published As
Publication number | Publication date |
---|---|
EP0000931B1 (de) | 1982-04-14 |
US4162193A (en) | 1979-07-24 |
PT68428A (en) | 1978-09-01 |
IE781674L (en) | 1979-02-19 |
JPS6210639B2 (de) | 1987-03-07 |
IT1106626B (it) | 1985-11-11 |
JPS5446890A (en) | 1979-04-13 |
IE47315B1 (en) | 1984-02-22 |
IT7850747A0 (it) | 1978-08-16 |
DK365478A (da) | 1979-02-20 |
ES472701A1 (es) | 1979-02-16 |
DE2861737D1 (en) | 1982-05-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US4526783A (en) | Antibiotic from S. clavuligerus | |
US3239394A (en) | Process for producing 7-amino-cephalosporanic acid | |
CA1049532A (en) | Antibiotics | |
US4162193A (en) | Enzymatic cleavage of N-acyl-thienamycins | |
US6156534A (en) | Synthesis of β-lactam antibacterials using soluble side chain esters and enzyme acylase | |
EP0000932B1 (de) | Herstellung von N-acyl-Thienamycinen | |
EP0001567B1 (de) | Thienamycin verwandte Antibiotika PS-6 und PS-7, Verfahren zu ihrer Herstellung sowie sie enthaltende Zusammensetzungen | |
Ito et al. | A novel β-lactamase inhibitor, SF-2103 A produced by a Streptomyces | |
EP0052974B1 (de) | Enzymatische Deesterifikationen | |
US4587333A (en) | Cephalosporins and their production | |
CS269952B2 (en) | Method of enduracidine production | |
US4656288A (en) | Antibiotics, their production and use | |
US3899394A (en) | Production of antibacterial agents | |
US3905868A (en) | Enzymatic deacylation of benzyl- and phenoxymethylpenicillin tetrazoles | |
CA1238594A (en) | Antibiotics, tan-558, their production and use | |
US4205068A (en) | β-Lactamase inhibitor EM4615 | |
Serizawa et al. | Enzymatic conversion of cephamycin C by D-amino acid oxidase from Trigonopsis variabilis | |
EP0046596B1 (de) | Antibiotikum PA-39504-X3, Verfahren zu seiner Herstellung und pharmazeutische Zubereitungen | |
EP0079244B1 (de) | Pluracidomycin B,C und D und deren Analoge, ihre Herstellung und ein dabei verwendbarer Mikroorganismus | |
US3616223A (en) | Penicillin intermediate | |
US4448723A (en) | Antibiotics PA-41746-B and C | |
US4061649A (en) | Clavulanic acid sulphates | |
US4667027A (en) | Cephem compounds and their production | |
US4468350A (en) | KA-6643-Series antibiotics, process for producing same and medical composition containing same | |
US3717548A (en) | Method for preparing aminocyclohexylpenicillin |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
AK | Designated contracting states |
Designated state(s): BE CH DE FR GB LU NL SE |
|
17P | Request for examination filed | ||
GRAA | (expected) grant |
Free format text: ORIGINAL CODE: 0009210 |
|
AK | Designated contracting states |
Designated state(s): BE CH DE FR GB LU NL SE |
|
REF | Corresponds to: |
Ref document number: 2861737 Country of ref document: DE Date of ref document: 19820527 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: LU Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 19820831 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: SE Payment date: 19830630 Year of fee payment: 6 Ref country code: BE Payment date: 19830630 Year of fee payment: 6 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: LU Payment date: 19830706 Year of fee payment: 6 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: SE Effective date: 19840819 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: BE Effective date: 19890831 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: CH Payment date: 19910606 Year of fee payment: 14 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: FR Payment date: 19910628 Year of fee payment: 14 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: GB Payment date: 19910701 Year of fee payment: 14 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: DE Payment date: 19910826 Year of fee payment: 14 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: NL Payment date: 19910831 Year of fee payment: 14 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: GB Effective date: 19920818 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: CH Effective date: 19920831 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: NL Effective date: 19930301 |
|
GBPC | Gb: european patent ceased through non-payment of renewal fee |
Effective date: 19920818 |
|
NLV4 | Nl: lapsed or anulled due to non-payment of the annual fee | ||
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: FR Effective date: 19930430 |
|
REG | Reference to a national code |
Ref country code: CH Ref legal event code: PL |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: DE Effective date: 19930501 |
|
REG | Reference to a national code |
Ref country code: FR Ref legal event code: ST |
|
EUG | Se: european patent has lapsed |
Ref document number: 78100699.4 Effective date: 19850612 |
|
PLBE | No opposition filed within time limit |
Free format text: ORIGINAL CODE: 0009261 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT |